Emblem Corp Preparing for Growth as Cannabis Legalization Moves Forward in Canada

Emblem Corp. (OTCPK: EMMBF) is a licensed producer of medical cannabis under the Canadian Access to Cannabis for Medical Purposes Regulations. Led by a team of cannabis experts and former healthcare and pharma executives, the Company has three distinct verticals – cannabis production, patient education centers, and pharmaceutical development. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange and EMMBF on the OTC markets.


Company’ business model and strategy:

On May 29th, the company reported financial and operating results for the first quarter ended March 31, 2018. Along with record sales and registered patient counts, EMMBF’s first quarter progressed rapidly in all areas (including market, operations and financial flexibility) as the company focused on executing its multi-year plan.


Key Highlights of 2018

  • Generated $1.3 million in revenue & Cannabis oil sales represented 29% of Q1 patient revenue
  • 2,950 registered patients as of March 31, 2018
  • Signed a key supplier agreement to become a medical cannabis supplier to Shoppers Drug Mart Inc.
  • $53.8 million financing increased cash balance to $83.8 million as at March 31, 2018
  • Purchased remaining 50% of GrowWise Health Limited
  • Progressed on expansion plans to increase annual capacity to approximately 17,000kg
  • Construction progressing on 30,000 square foot Phase 3 expansion at the Woodslee Production Facility with GMP extraction facility, laboratory and pharmaceutical production facility
  • Invested in Fire & Flower Inc. and entered into the 3-year preferred supplier agreement
  • Increased patient count 22% to approximately 3,600 patients at May 28, 2018, since March 31, 2018
  • Commenced R&D on oral sustained release formulations in collaboration with Canntab Therapeutics Limited (“Canntab”)
  • Commenced inventory build for the legalization of adult-use recreational cannabis in Canada


Key growth driver over the near to medium term:

In an attempt to further grow its market share in the lucrative cannabis business, Emblem Corp continues to utilize its strong balance sheet to execute on its expansion plans for annual dried flower volumes initially to 17,000kg and to complete its 30,000-square foot expansion which includes a GMP certified manufacturing facility with an advanced research lab. The GMP certification will support international product exports. Further, Emblem is making strategic investments in pharmaceutical research and development, clinical research, marketing and promotion, product development and licensing, allowing the Company to maintain its leadership position within the medical-use market while preparing Emblem for a unique and competitive advantage in the recreational adult-use market.


From a relative standpoint, analysts expect that the company would continue to leverage on its extremely strong liquidity and relatively diverse business verticals. Furthermore, Emblem Corp’ strategic partnerships are likely to help the company in further diversifying and strengthening its revenue streams.


Analysts tracking the stock believes that EMMBF is presently at a critical inflection point and 2018 could be a year of multiple achievements for the company, as it aggressively pursues its commercialization, diversification and overall expansion strategies.  From a sectoral viewpoint, the accelerated interest of the market in Cannabis space has also made EMMBF a favourite play in the sector. Also, the muted performance of the stock in the recent past has created an incredible buying opportunity with significant upside potential. Taking a valuation call on the stock and the sector, share now ruling at $1.48, can move to a level of $2.70 in next few months.  


About the Company: Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR. Led by a team of cannabis experts and former healthcare and pharma executives, the Company has three distinct verticals – cannabis production, patient education centers, and pharmaceutical development. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange and EMMBF on the OTC markets.


Key Operating Units and brands:

Financials for the First Quarter of 2018:

  • Revenues increased to $1,277,000 in Q1 2018 from $903,000 in Q1 2017, an increase of 41%.
  • Gross profit for the three months ended March 31, 2018, was $182,000 compared to a gross loss of $89,000 for the prior year comparable period, an increase of $271,000 or 304% due to higher revenues and a higher unrealized gain on changes in fair value of biological assets. With a total of five grow rooms completed and the receipt of the license for sale of cannabis oil during late 2017, the Company expects to generate a steady increase in gross profit throughout the remainder of 2018.


Key risk factors and potential stock drivers:

Continuing expansion of the legalized cannabis sector could be a catalyst for the company’s shares;

Notwithstanding EMMBF unique and differentiating factors, the company is still exposed to risk related to competition and peer pressure. There are other highly diversified cannabis companies in the industry. Additionally, there’s a cannabis ETF that recently launched for even more diversification;

Company’ ability to grow revenue while significantly improving its profitability will continue to remain a critical price sensitivity for the company;

The company continues to face significant regulatory risks and uncertainty, while at the same time additional states legalize cannabis.


Stock Chart:



  • On Wednesday, June 13th, 2018, EMMBF is trading at $1.13, on volume of 109K shares exchanging hands. Market capitalization is $136 million. The current RSI is 45.46
  • In the past 52 weeks, shares of EMMBF have traded as low as $.93 and as high as $22.20
  • At $1.13, shares of EMMBC are trading around its 50-day moving average (MA) at $1.15 and below its 200-day moving average (MA) at $1.33


Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.